Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement

[1]  M. B. Cunha-Neto,et al.  How to manage intolerance to dopamine agonist in patients with prolactinoma , 2023, Pituitary.

[2]  A. Akirov,et al.  The Role of Aromatase Inhibitors in Male Prolactinoma , 2023, Journal of clinical medicine.

[3]  M. AlMalki,et al.  Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review , 2023, Cureus.

[4]  Xue-yan Wan,et al.  Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives , 2022, Current Medical Science.

[5]  P. Chanson.  Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists. , 2022, Best practice & research. Clinical endocrinology & metabolism.

[6]  M. Takashima,et al.  ENDOSCOPIC ENDONASAL TRANSSPHENOIDAL SURGERY FOR PATIENTS WITH PROLACTINOMAS: Indications and Outcomes. , 2022, World neurosurgery.

[7]  G. Raverot,et al.  Immunotherapy in pituitary carcinomas and aggressive pituitary tumors. , 2022, Best practice & research. Clinical endocrinology & metabolism.

[8]  Rushikesh S. Joshi,et al.  Correlation between tumor volume and serum prolactin and its effect on surgical outcomes in a cohort of 219 prolactinoma patients. , 2022, Journal of neurosurgery.

[9]  S. Melmed,et al.  Acromegaly: pathogenesis, diagnosis, and management. , 2022, The lancet. Diabetes & endocrinology.

[10]  P. Chanson,et al.  Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. , 2022, European journal of endocrinology.

[11]  O. Dekkers,et al.  Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients , 2022, European journal of endocrinology.

[12]  M. Gee,et al.  Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager , 2022, Diagnostics.

[13]  P. Chanson,et al.  Prolactin immunoassay: does the high-dose hook effect still exist? , 2022, Pituitary.

[14]  W. Bashari,et al.  Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery , 2022, Pituitary.

[15]  A. Kolias,et al.  11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy , 2022, Pituitary.

[16]  I. Shimon,et al.  Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma , 2022, Pituitary.

[17]  Phillip A. Choi,et al.  The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus , 2022, Pituitary.

[18]  J. Bertherat,et al.  Clinical Biology of the Pituitary Adenoma , 2022, Endocrine reviews.

[19]  J. Manson,et al.  Oral contraceptive and menopausal hormone therapy use and risk of pituitary adenoma: cohort and case-control analyses. , 2021, The Journal of clinical endocrinology and metabolism.

[20]  R. Salvatori,et al.  Speed of response to dopaminergic agents in prolactinomas , 2021, Endocrine.

[21]  M. Taquet,et al.  Should pituitary carcinoma be treated using a NET‐like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy , 2021, Clinical endocrinology.

[22]  P. Chanson,et al.  Consensus on diagnosis and management of Cushing's disease: a guideline update. , 2021, The lancet. Diabetes & endocrinology.

[23]  J. Bertherat,et al.  Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas, a cohort study. , 2021, European journal of endocrinology.

[24]  P. Chanson,et al.  Pituitary adenoma in patients with multiple endocrine neoplasia type 1 - a cohort study. , 2021, European journal of endocrinology.

[25]  J. V. Van Gompel,et al.  Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis , 2021, Pituitary.

[26]  J. Trouillas,et al.  Aggressive pituitary tumours and pituitary carcinomas , 2021, Nature Reviews Endocrinology.

[27]  S. Leucht,et al.  Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis , 2021, Schizophrenia Research.

[28]  Qun Li,et al.  Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis , 2021, International journal of endocrinology.

[29]  P. Chanson,et al.  ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. , 2021, European journal of endocrinology.

[30]  R. Simó,et al.  Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. , 2021, European journal of endocrinology.

[31]  H. Randeva,et al.  Mechanisms of Central Hypogonadism , 2021, International journal of molecular sciences.

[32]  Nidhi Agrawal,et al.  Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis. , 2021, World neurosurgery.

[33]  S. Gaztambide,et al.  Clinical and genetic characteristics in patients under 30 years with sporadic pituitary adenomas. , 2021, European journal of endocrinology.

[34]  F. Besag,et al.  Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review , 2021, CNS Drugs.

[35]  A. McCormack.  Childhood‐onset prolactinomas—Should earlier surgery be considered? , 2021, Clinical endocrinology.

[36]  P. Chanson,et al.  Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas , 2021, Endocrine.

[37]  J. Honegger,et al.  Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases. , 2021, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[38]  C. Muir,et al.  Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment , 2021, Endocrine.

[39]  M. Brandi,et al.  Multiple Endocrine Neoplasia Type 1: Latest Insights. , 2020, Endocrine reviews.

[40]  S. Melmed,et al.  EGFR/ErbB2 targeting lapatinib therapy for aggressive prolactinomas. , 2020, The Journal of clinical endocrinology and metabolism.

[41]  C. Yedinak,et al.  Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas , 2020, Frontiers in Endocrinology.

[42]  R. Ness-Abramof,et al.  Role of Cannulated Prolactin Test in Evaluation of Hyperprolactinemia - A Retrospective Study. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[43]  R. Dorizzi,et al.  Hypeprolactinemia: still an insidious diagnosis , 2020, Endocrine.

[44]  N. Shah,et al.  Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline. , 2020, The Journal of clinical endocrinology and metabolism.

[45]  R. Salvatori,et al.  Predictors of the Response to Dopaminergic Therapy in Patients with Prolactinoma. , 2020, The Journal of clinical endocrinology and metabolism.

[46]  P. Chanson,et al.  Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma. , 2020, European journal of endocrinology.

[47]  E. Laws,et al.  Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size. , 2020, Journal of neurosurgery.

[48]  A. Ioachimescu,et al.  The Role of Dopamine Agonists in Pituitary Adenomas. , 2020, Endocrinology and metabolism clinics of North America.

[49]  M. Maksymowicz,et al.  Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery , 2020, Frontiers in Endocrinology.

[50]  Jianyu Zhou,et al.  Somatic SF3B1 hotspot mutation in prolactinomas , 2020, Nature Communications.

[51]  A. Heaney,et al.  Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas , 2020, Reviews in Endocrine and Metabolic Disorders.

[52]  A. Giustina,et al.  Hyperprolactinemia and bone , 2020, Pituitary.

[53]  S. Melmed.  Pituitary-Tumor Endocrinopathies. , 2020, The New England journal of medicine.

[54]  S. M. D. De Sousa,et al.  Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. , 2020, The Journal of clinical endocrinology and metabolism.

[55]  C. Stratakis,et al.  Aggressive pituitary tumors in the young and elderly , 2020, Reviews in Endocrine and Metabolic Disorders.

[56]  S. Petersenn.  Biochemical diagnosis in prolactinomas: some caveats , 2019, Pituitary.

[57]  J. Honegger,et al.  Surgery for prolactinomas: a better choice? , 2019, Pituitary.

[58]  I. Shimon,et al.  Prolactinomas in males: any differences? , 2019, Pituitary.

[59]  M. Bronstein,et al.  Prolactinomas in pregnancy: considerations before conception and during pregnancy , 2019, Pituitary.

[60]  J. Honegger,et al.  Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas - a German survey. , 2019, The Journal of clinical endocrinology and metabolism.

[61]  J. Abucham,et al.  A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas , 2019, Pituitary.

[62]  Y. Greenman.  Prolactinomas and menopause: any changes in management? , 2019, Pituitary.

[63]  O. Dekkers,et al.  Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis , 2019, The Journal of clinical endocrinology and metabolism.

[64]  M. Fleseriu,et al.  Magnetic resonance imaging in the management of prolactinomas; a review of the evidence , 2020 .

[65]  G. Raverot,et al.  Aggressive prolactinomas: how to manage? , 2019, Pituitary.

[66]  D. Carvalho,et al.  Dopamine agonists in prolactinomas: when to withdraw? , 2019, Pituitary.

[67]  O. Dekkers,et al.  Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis , 2019, The Journal of clinical endocrinology and metabolism.

[68]  Y. Shoenfeld,et al.  Prolactin and autoimmunity: The hormone as an inflammatory cytokine. , 2019, Best practice & research. Clinical endocrinology & metabolism.

[69]  F. Meyer,et al.  Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure. , 2019, World neurosurgery.

[70]  Yong Zhang,et al.  Multidisciplinary team efforts improve the surgical outcomes of sellar region lesions during pregnancy , 2019, Endocrine.

[71]  N. Karavitaki,et al.  Hyperprolactinaemia , 2019, Journal of clinical medicine.

[72]  M. Wurm,et al.  Start low, go slowly – mental abnormalities in young prolactinoma patients under cabergoline therapy , 2019, Journal of pediatric endocrinology & metabolism : JPEM.

[73]  E. Laws,et al.  The Role of Surgery in the Management of Prolactinomas. , 2019, Neurosurgery clinics of North America.

[74]  I. Shimon,et al.  Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years , 2019, Endocrine.

[75]  M. Arosio,et al.  Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas , 2019, Hormones and Cancer.

[76]  P. Chanson,et al.  The epidemiology, diagnosis and treatment of Prolactinomas:The old and the new. , 2019, Best practice & research. Clinical endocrinology & metabolism.

[77]  I. Mendichovszky,et al.  Modern imaging of pituitary adenomas. , 2019, Best practice & research. Clinical endocrinology & metabolism.

[78]  D. Maiter.  Management of Dopamine Agonist-Resistant Prolactinoma , 2019, Neuroendocrinology.

[79]  M. Buchfelder,et al.  Surgery for Prolactinomas to Date , 2019, Neuroendocrinology.

[80]  J. Chambers,et al.  Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology , 2019, Clinical endocrinology.

[81]  M. Bergsneider,et al.  Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas , 2019, The Journal of clinical endocrinology and metabolism.

[82]  Jacques Young,et al.  PCOS and Hyperprolactinemia: what do we know in 2019? , 2019, Clinical medicine insights. Reproductive health.

[83]  A. Hoffman,et al.  Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. , 2019, European journal of endocrinology.

[84]  M. Fleseriu,et al.  Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a “Pituitary Society” survey , 2018, Pituitary.

[85]  I. Shimon.  Giant Prolactinomas , 2018, Neuroendocrinology.

[86]  C. Villabona,et al.  Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes , 2018, Hormone and Metabolic Research.

[87]  Qing Liu,et al.  The Chance of Permanent Cure for Micro- and Macroprolactinomas, Medication or Surgery? A Systematic Review and Meta-Analysis , 2018, Front. Endocrinol..

[88]  D. Maiter,et al.  T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists , 2018, Endocrine.

[89]  W. Drake,et al.  A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline , 2018, The Journal of clinical endocrinology and metabolism.

[90]  E. Knosp,et al.  Endoscopic Transsphenoidal Surgery of Microprolactinomas: A Reappraisal of Cure Rate Based on Radiological Criteria. , 2018, Neurosurgery.

[91]  S. Yarman,et al.  Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas , 2018, Pituitary.

[92]  S. Sinha,et al.  Pituitary tumour apoplexy within prolactinomas in children: a more aggressive condition? , 2018, Pituitary.

[93]  N. Karavitaki,et al.  Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal , 2018, Clinical endocrinology.

[94]  I. Hochberg,et al.  Management of cystic prolactinomas: a review , 2018, Pituitary.

[95]  W. Zhao,et al.  Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review , 2018, Metabolic Brain Disease.

[96]  O. Dekkers,et al.  Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. , 2018, European journal of endocrinology.

[97]  J. Jesser,et al.  Clinical Features and Response to Treatment of Prolactinomas in Children and Adolescents: A Retrospective Single-Centre Analysis and Review of the Literature , 2018, Hormone Research in Paediatrics.

[98]  H. Martin,et al.  Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues. , 2018, The Clinical biochemist. Reviews.

[99]  F. Alosaimi,et al.  Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications , 2018, International journal of psychiatry in clinical practice.

[100]  S. M. D. De Sousa,et al.  Vasculogenic hyperprolactinemia: severe prolactin excess in association with internal carotid artery aneurysms , 2017, Pituitary.

[101]  N. Karavitaki,et al.  Prolactinomas diagnosed in the postmenopausal period: Clinical phenotype and outcomes , 2017, Clinical endocrinology.

[102]  P. Cohen-Kettenis,et al.  Endocrine Treatment of Gender‐Dysphoric/Gender‐Incongruent Persons: An Endocrine Society* Clinical Practice Guideline , 2017, The Journal of clinical endocrinology and metabolism.

[103]  M. Overgaard,et al.  Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia , 2017, Clinical chemistry and laboratory medicine.

[104]  M. den Heijer,et al.  Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment. , 2017, LGBT health.

[105]  E. Soto-Pedre,et al.  Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study , 2017, Endocrine connections.

[106]  P. Chanson,et al.  Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement , 2017, Pituitary.

[107]  M. Heijer,et al.  Prolactin levels during short‐ and long‐term cross‐sex hormone treatment: an observational study in transgender persons , 2017, Andrologia.

[108]  P. Chanson,et al.  Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. , 2017, European journal of endocrinology.

[109]  Christopher T. Chan,et al.  Hyperprolactinemia in end‐stage renal disease and effects of frequent hemodialysis , 2017, Hemodialysis international. International Symposium on Home Hemodialysis.

[110]  P. Chanson,et al.  Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas , 2017, Journal of the Endocrine Society.

[111]  M. Molitch.  Diagnosis and Treatment of Pituitary Adenomas: A Review , 2017, JAMA.

[112]  M. Murad,et al.  Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[113]  N. Karavitaki,et al.  THERAPY OF ENDOCRINE DISEASE: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature. , 2016, European journal of endocrinology.

[114]  A. Klibanski,et al.  Dopamine Agonists Can Reduce Cystic Prolactinomas. , 2016, The Journal of clinical endocrinology and metabolism.

[115]  M. Vrkljan,et al.  Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link? , 2016, Endocrine research.

[116]  M. Reni,et al.  Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas , 2016, Journal of Neuro-Oncology.

[117]  J. Honegger,et al.  Diagnosis of Primary Hypophysitis in Germany. , 2015, The Journal of clinical endocrinology and metabolism.

[118]  A. Tirosh,et al.  SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[119]  H. Sørensen,et al.  Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. , 2015, European journal of endocrinology.

[120]  S. Aylwin,et al.  Importance of cannulated prolactin test in the definition of hyperprolactinaemia , 2015, Pituitary.

[121]  M. Molitch.  Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. , 2015, European journal of endocrinology.

[122]  A. Mamelak,et al.  Hyperprolactinemia due to spontaneous intracranial hypotension. , 2015, Journal of neurosurgery.

[123]  L. Tshibanda,et al.  Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference , 2015, Neuroradiology.

[124]  M. Levy,et al.  Pituitary tumor apoplexy in adolescents. , 2015, World neurosurgery.

[125]  P. Chanson,et al.  Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. , 2015, The Journal of clinical endocrinology and metabolism.

[126]  L. Vilar,et al.  Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile? , 2015, Front. Endocrinol..

[127]  A. Tirosh,et al.  Hypopituitarism patterns and prevalence among men with macroprolactinomas , 2015, Pituitary.

[128]  G. Yenokyan,et al.  Second attempt to withdraw cabergoline in prolactinomas: a pilot study , 2014, Pituitary.

[129]  M. Cosottini,et al.  Lower Prolactin Levels During Cabergoline Treatment are Associated to Tumor Shrinkage in Prolactin Secreting Pituitary Adenoma , 2014, Hormone and Metabolic Research.

[130]  D. Maiter,et al.  Therapy of endocrine disease: the challenges in managing giant prolactinomas. , 2014, European journal of endocrinology.

[131]  C. Benbassat,et al.  Women with prolactinomas presented at the postmenopausal period , 2014, Endocrine.

[132]  R. Weil,et al.  Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? , 2014, Pituitary.

[133]  M. Gadelha,et al.  Giant prolactinomas: the therapeutic approach , 2013, Clinical endocrinology.

[134]  T. Yoshimoto,et al.  Transsphenoidal microsurgical results of female patients with prolactinomas , 2013, Clinical Neurology and Neurosurgery.

[135]  P. Chanson,et al.  Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. , 2012, European journal of endocrinology.

[136]  Jacques Young,et al.  Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. , 2012, The Journal of clinical investigation.

[137]  V. Mehta,et al.  Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature. , 2012, Neurosurgical focus.

[138]  C. Raftopoulos,et al.  Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. , 2012, European journal of endocrinology.

[139]  Jacques Young,et al.  Male acquired hypogonadotropic hypogonadism: diagnosis and treatment. , 2012, Annales d'endocrinologie.

[140]  E. Menis,et al.  Vertebral fractures in males with prolactinoma , 2011, Endocrine.

[141]  A. Quiñones‐Hinojosa,et al.  Effect of dopaminergic drug treatment on surgical findings in prolactinomas , 2011, Pituitary.

[142]  C. Benbassat,et al.  Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression , 2011, Pituitary.

[143]  E. Menis,et al.  High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas , 2011, Pituitary.

[144]  A. Hoffman,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[145]  S. Hunter,et al.  Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. , 2010, The Journal of clinical endocrinology and metabolism.

[146]  E. A. McKay,et al.  Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. , 2009, The Journal of clinical endocrinology and metabolism.

[147]  G. Yenokyan,et al.  Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. , 2009, The Journal of clinical endocrinology and metabolism.

[148]  Rogério Silicani Ribeiro,et al.  Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. , 2009, European journal of endocrinology.

[149]  Chun-Hsin Chen,et al.  Cabergoline-induced psychotic exacerbation in schizophrenic patients. , 2008, General hospital psychiatry.

[150]  M. Molitch.  Drugs and prolactin , 2008, Pituitary.

[151]  G. Guyatt,et al.  A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. , 2008, The Journal of clinical endocrinology and metabolism.

[152]  F. Casanueva,et al.  Hyperprolactinemia and prolactinomas. , 2008, Endocrinology and metabolism clinics of North America.

[153]  N. Karavitaki,et al.  Do the limits of serum prolactin in disconnection hyperprolactinaemia need re‐definition? A study of 226 patients with histologically verified non‐functioning pituitary macroadenoma , 2006, Clinical endocrinology.

[154]  P. Cappabianca,et al.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas , 2006, Clinical endocrinology.

[155]  A. Colao,et al.  Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.

[156]  B. Schaller.  Gender-related differences in prolactinomas. A clinicopathological study. , 2005, Neuro endocrinology letters.

[157]  P. Cappabianca,et al.  Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. , 2004, The Journal of clinical endocrinology and metabolism.

[158]  S. Melmed.  Mechanisms for pituitary tumorigenesis: the plastic pituitary. , 2003, The Journal of clinical investigation.

[159]  M. Vance,et al.  Quality of Life in Patients with a Pituitary Adenoma , 2003, Pituitary.

[160]  H. Nishioka,et al.  Growth potential of prolactinomas in men: is it really different from women? , 2003, Surgical neurology.

[161]  P. Cappabianca,et al.  Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. , 2003, European journal of endocrinology.

[162]  M. Losa,et al.  Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. , 2002, The Journal of clinical endocrinology and metabolism.

[163]  J. Wass,et al.  The effect of the menopause on prolactin levels in patients with hyperprolactinaemia , 2001, Clinical endocrinology.

[164]  D. Pauler,et al.  Primary medical therapy of micro- and macroprolactinomas in men. , 2000, The Journal of clinical endocrinology and metabolism.

[165]  Kane,et al.  Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition , 1999, Clinical endocrinology.

[166]  L. Balint-perić,et al.  Changes in prolactin levels with the menopause: the effects of estrogen/androgen and calcitonin treatment. , 1997, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[167]  J. Donckier,et al.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. , 1997, The Journal of clinical endocrinology and metabolism.

[168]  Y. Maor,et al.  Hyperprolactinemia in postmenopausal women. , 1997, Fertility and sterility.

[169]  A. Iranmanesh,et al.  Neuroendocrine alterations in the somatotropic and lactotropic axes in uremic men. , 1994, European journal of endocrinology.

[170]  van 't Verlaat Jw,et al.  [Hyperprolactinemia and prolactinomas]. , 1991, Nederlands tijdschrift voor geneeskunde.

[171]  K. Kovacs,et al.  Clonal origin of pituitary adenomas. , 1990, The Journal of clinical endocrinology and metabolism.

[172]  J. Vienken,et al.  Clinical Evaluation of a New High-Flux Cellulose Acetate Membrane , 1989, The International journal of artificial organs.

[173]  B. Sherman,et al.  The natural history of untreated hyperprolactinemia: a prospective analysis. , 1989, The Journal of clinical endocrinology and metabolism.

[174]  J. Prior,et al.  Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. , 1987, The Journal of clinical endocrinology and metabolism.

[175]  J. López-Novoa,et al.  Molecular heterogeneity of circulating prolactin in chronic uremic men and renal transplant recipients. , 1986, The Journal of clinical endocrinology and metabolism.

[176]  M. Molitch,et al.  Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. , 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[177]  Abraham Weizman,et al.  Sexual Dysfunction Associated with Hyperprolactinemia in Males and Females Undergoing Hemodialysis , 1983, Psychosomatic medicine.

[178]  J. Ratcliffe,et al.  HYPERPROLACTINAEMIA IN RENAL DISEASE , 1978, Clinical endocrinology.

[179]  S. McCartney,et al.  Pituitary magnetic resonance imaging use in the posttreatment follow-up of secreting pituitary adenomas , 2021 .

[180]  O. Dekkers,et al.  European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. , 2018, European journal of endocrinology.

[181]  S. Lin,et al.  Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis , 2017, Endocrine.

[182]  A. Claviez,et al.  Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis , 2017, European Journal of Pediatrics.

[183]  이영기.  Early prediction of long-term response to cabergoline in patients with macroprolactinomas , 2014 .

[184]  A. Wieck,et al.  Antipsychotic-Induced Hyperprolactinaemia , 2012, Drugs.

[185]  C. Nimsky,et al.  Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. , 2008, European journal of endocrinology.

[186]  J. Mennella,et al.  Short-term effects of alcohol consumption on the hormonal milieu and mood states in nulliparous women. , 2006, Alcohol.

[187]  P. Kopp,et al.  Men with Acquired Hypogonadotropic Hypogonadism Treated with Testosterone may be Fertile , 2004, Pituitary.

[188]  A. J. Kumar,et al.  Pituitary adenomas: possible role of bromocriptine in intratumoral hemorrhage. , 1989, Radiology.

[189]  GrADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2022 .